Wellington Management Group LLP Decreases Position in Qiagen N.V. $QGEN

Wellington Management Group LLP lessened its position in Qiagen N.V. (NYSE:QGEN) by 10.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,330,248 shares of the company’s stock after selling 2,693,692 shares during the period. Wellington Management Group LLP owned about 0.10% of Qiagen worth $1,035,906,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in QGEN. Smartleaf Asset Management LLC increased its position in shares of Qiagen by 1,383.3% during the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after acquiring an additional 830 shares in the last quarter. MAI Capital Management lifted its position in Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after acquiring an additional 889 shares in the last quarter. Allworth Financial LP boosted its stake in Qiagen by 260.1% during the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after purchasing an additional 796 shares during the last quarter. GAMMA Investing LLC boosted its stake in Qiagen by 375.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after purchasing an additional 980 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in shares of Qiagen by 64.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,610 shares of the company’s stock worth $71,000 after purchasing an additional 628 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on QGEN shares. JPMorgan Chase & Co. upped their price target on Qiagen from $55.00 to $60.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Barclays set a $58.00 price objective on Qiagen and gave the stock an “overweight” rating in a report on Friday, February 6th. UBS Group set a $52.00 target price on shares of Qiagen in a research note on Monday, February 9th. Citigroup dropped their price target on shares of Qiagen from $55.40 to $55.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Finally, Robert W. Baird set a $53.00 price target on shares of Qiagen in a research note on Friday, February 6th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Qiagen has a consensus rating of “Hold” and a consensus price target of $55.20.

Qiagen Stock Performance

QGEN opened at $40.59 on Friday. The company’s 50 day moving average is $49.32 and its 200 day moving average is $48.86. The company has a current ratio of 3.90, a quick ratio of 3.31 and a debt-to-equity ratio of 0.44. The company has a market cap of $8.57 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 2.01 and a beta of 0.70. Qiagen N.V. has a 12-month low of $40.14 and a 12-month high of $57.81.

Qiagen (NYSE:QGEN) last announced its earnings results on Thursday, February 5th. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. During the same period in the prior year, the company earned $0.61 earnings per share. The firm’s revenue was up 3.6% on a year-over-year basis. On average, equities research analysts predict that Qiagen N.V. will post 2.26 EPS for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.